Pompe Disease Clinical Trial
Official title:
A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy
Funding Source- FDA OOPD
The purpose of this study is to investigate the safety and efficacy of clenbuterol on motor
function in individuals with late-onset Pompe disease (LOPD) who are treated with enzyme
replacement therapy (ERT).
This is a 52 week Phase I/II double-blind, randomized, placebo-controlled study of adjunctive
clenbuterol in LOPD (Table 2, Section 6). All subjects will be evaluated at Week 0 and Week 6
to establish a baseline for motor function testing. At Week 6, subjects will be randomized
3:2 to clenbuterol or placebo, and evaluated for safety and efficacy during the Week 12 and
18 visits. The Investigational Drug Service will maintain double-blinding by providing either
the study drug or placebo (over-encapsulated tablets) directly to subjects. The drug (or
placebo) will be initiated at the Week 6 visit in a staged manner (first once daily and later
BID), and the dose will be increased at the Week 12 visit in a similarly staged manner to
minimize AEs and related attrition. All subjects will return for a final visit after a total
of 52 weeks in the study.
In terms of standard of care, the subject will have two clinical visits (charged to the
subject and/or the subject's insurance company), one at the initiation of the study drug
(baseline) and one at the study completion (52 weeks). Study drug will be attempted to be
initiated during the "off week", approximately one week following a dose of ERT, and ERT will
continue throughout the duration of the study. Thereafter, study visits will be during the
"off week". The 6, 12, and 18 week visits will be research visits (not charged to the subject
and/or the subject's insurance company) in order to determine subject's overall health status
and measure early signs of motor improvement. The initial dose of clenbuterol will be 40 mcg
per oral each morning for one week, followed by 40 mcg BID for the next 5 weeks until the
week 12 visit. If the 40 mcg BID per oral is well tolerated, the dose will be increased to 80
mcg each morning/40 mcg each evening for one week, followed by 80 mcg BID for the next 5
weeks until the Week 18 visit. If 80 mcg BID is tolerated at Week 18, the subject will
continue on that dose until Week 52.
Compliance will be discussed at the Week 6, Week 12, and Week 18 visits. The subject will
have phone visits during Week 1, 7, 13, 36, and 52, and compliance will be discussed then. We
will call subjects daily during the first week following initiation of study drug (Week 7)
and dosage escalation (Week 13) to support subjects through the early adverse effects of
tachyphylaxis that may lead to premature termination. An interim call will occur during Week
36 to monitor compliance. Subjects who admit non-compliance, missing >6 doses of the study
drug, will be considered non-compliant and withdrawn from the study. Subjects will be called
during Week 1 and Week 52, 3 days following the muscle biopsy. All phone calls will review
AEs (Table).
The efficacy of clenbuterol treatment during ERT in patients with LOPD will be evaluated with
muscle and pulmonary function testing as the primary endpoints. A secondary endpoint, the
urinary Glc4 biomarker, will be monitored when the subjects are evaluated at baseline, week
18 and week 52. The impact of enhanced CI-MPR-mediated uptake of GAA will be analyzed by
comparing the muscle function, pulmonary function, and biochemical correction of muscle in
subjects with LOPD treated with ERT, both prior to and during simultaneous β2 agonist
therapy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT01409486 -
Screening for Early Detection and Prevention of Pompe Disease in Israel Using Tandem Mass Spectrometry
|
N/A | |
Completed |
NCT00976352 -
Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT01665326 -
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
|
||
Completed |
NCT01758354 -
Newborn Screening Assay of Pompe's Disease
|
N/A | |
Recruiting |
NCT00231400 -
Pompe Disease Registry Protocol
|
||
Recruiting |
NCT04476550 -
Clinical Specimen Collection From Pompe Disease Patients
|
||
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Completed |
NCT01380743 -
Drug-drug Interaction Study
|
Phase 2 | |
Recruiting |
NCT05734521 -
Avalglucosidase Alfa Pregnancy Study
|
||
Completed |
NCT02742298 -
Pompe Disease QMUS and EIM
|
N/A | |
Terminated |
NCT02185651 -
A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction
|
Phase 1 | |
Completed |
NCT02654886 -
Safety and Effectiveness of Resistance Exercise Training in Patients With Pompe Disease.
|
N/A | |
Completed |
NCT02405598 -
Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease
|
Phase 4 | |
Completed |
NCT00701129 -
An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease
|
Phase 4 | |
Completed |
NCT01451879 -
Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies
|
N/A | |
Completed |
NCT02240407 -
Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease
|
Phase 1 | |
Completed |
NCT05073783 -
A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care Setting
|
||
Active, not recruiting |
NCT04093349 -
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
|
Phase 1/Phase 2 | |
Completed |
NCT02363153 -
Diet and Exercise in Pompe Disease
|
N/A | |
Completed |
NCT01410890 -
Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease
|
Phase 4 |